14,248 Shares in COMPASS Pathways plc (NASDAQ:CMPS) Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. bought a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 14,248 shares of the company’s stock, valued at approximately $54,000.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of COMPASS Pathways in the fourth quarter worth approximately $41,000. Wealthfront Advisers LLC bought a new position in COMPASS Pathways during the 4th quarter worth approximately $43,000. Flagship Harbor Advisors LLC bought a new stake in shares of COMPASS Pathways in the 4th quarter valued at $43,000. Conservest Capital Advisors Inc. increased its position in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock worth $51,000 after buying an additional 3,000 shares during the period. Finally, Essential Planning LLC. bought a new position in COMPASS Pathways during the fourth quarter worth $70,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Trading Up 4.7 %

Shares of COMPASS Pathways stock opened at $3.10 on Friday. The stock has a market capitalization of $287.29 million, a PE ratio of -1.41 and a beta of 2.29. COMPASS Pathways plc has a 52 week low of $2.88 and a 52 week high of $10.31. The stock has a 50 day moving average price of $3.90 and a two-hundred day moving average price of $4.85. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, equities analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CMPS shares. Canaccord Genuity Group decreased their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of COMPASS Pathways in a report on Tuesday, March 4th. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday, February 27th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $21.83.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.